Caribou Biosciences Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -85.0% | -31.7% | +42.6% | -41.6% | +2.6% | +13.3% | +13.3% | -17.6% | +79.3% | -39.2% | -37.5% | – | |
| – | -93.1% | -64.0% | +20.6% | +3,383.8% | +0.1% | -94.2% | -25.5% | +1,625.8% | -97.0% | -4.8% | – | – | |
| – | – | +8.5% | +51.7% | -1,165.8% | – | – | +124.4% | -1,575.7% | – | -55.6% | -14.2% | – | |
| – | +9.4% | +8.0% | +5.0% | -14.3% | +0.1% | +16.6% | -22.1% | -19.1% | +6.3% | -13.5% | -8.1% | – | |
| – | +0.1% | +50.6% | -21.6% | -48.3% | +76.5% | -7.2% | +6.9% | -11.6% | -6.7% | -6.0% | -2.1% | – | |
| – | +301.9% | +22.3% | -3.4% | -77.4% | +6.2% | +292.5% | +12.5% | -81.2% | +252.2% | -13.5% | -4.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -467.9% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.